Jiangsu Ab&B Biotechnology

Jiangsu Ab&B Biotechnology is a clinical-stage biopharmaceutical company headquartered in Taizhou, China, specializing in the development of innovative biologics and high-quality biosimilars. The company leverages its proprietary high-efficiency recombinant protein expression platform to advance a pipeline primarily focused on bone metabolism, oncology, and autoimmune diseases. Its lead candidate, AB-001, is a recombinant humanized anti-RANKL monoclonal antibody currently in late-stage clinical development for osteoporosis and bone metastases. Ab&B Biotechnology operates within the China Medical City (CMC) ecosystem, utilizing integrated R&D and manufacturing capabilities to bring affordable biological therapies to market. The firm is committed to addressing significant unmet medical needs through scientific excellence and efficient drug development processes.